Since the current strategic period began in 2016, Gavi has focused on taking a long-term approach to developing and maintaining healthy markets for the critical vaccines we support. We are now seeing this work come to fruition. This has led to greater stability and supply security in important vaccine markets, providing countries with the confidence that supplies will be available to meet their demand.
Moderate levels of healthy dynamics in three key vaccine markets (pentavalent, pneumococcal and yellow fever) represent a significant achievement – particularly in the market for pentavalent vaccine – and will require continued work to sustain. Following a series of price drops since 2016, this market has now reached a level at which it is vital to maintain stability, while minimising risks to the security of supply. Further price reductions are neither expected nor desired, as they could potentially undermine this essential market. Gavi’s long-term ambition is to improve the health of other vaccine markets, recognising that changes in market conditions take time and are often interlinked with global markets. Importantly, eight vaccine markets were again assessed in 2019 as having sufficient and uninterrupted supply of appropriate vaccines.